GRC-17536
| Code | Size | Price |
|---|
| TAR-T31995-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
GRC-17536 is an orally available, potent, and selective transient receptor potential anchor protein 1 (TRPA1) inhibitor that has been shown to be highly effective in the treatment of inflammation and neuropathic pain in animal models. The selectivity of GRC-17536 is more than 1000 times higher than that of other TRPs, numerous GPCRs, enzymes, and other ion channels.
CAS:
1649479-05-9
Formula:
0
Molecular Weight:
0
Purity:
0.98
SMILES:
NA
References
1. Mukhopadhyay I, Kulkarni A, Aranake S, Karnik P, Shetty M, Thorat S, Ghosh I, Wale D, Bhosale V, Khairatkar-Joshi N. Transient receptor potential ankyrin 1 receptor activation in vitro and in vivo by pro-tussive agents: GRC 17536 as a promising anti-tussive therapeutic. PLoS One. 2014 May 12;9(5):e97005. doi: 10.1371/journal.pone.0097005. eCollection 2014. PubMed PMID: 24819048; PubMed Central PMCID: PMC4018403.
2. Mukhopadhyay I, Gomes P, Aranake S, Shetty M, Karnik P, Damle M, Kuruganti S, Thorat S, Khairatkar-Joshi N. Expression of functional TRPA1 receptor on human lung fibroblast and epithelial cells. J Recept Signal Transduct Res. 2011 Oct;31(5):350-8. doi: 10.3109/10799893.2011.602413. Epub 2011 Aug 17. PubMed PMID: 21848366.